Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
暂无分享,去创建一个
[1] J. Ge,et al. Efficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysis. , 2011, European journal of internal medicine.
[2] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[3] T. Golde,et al. Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases , 2009, Alzheimers Res Ther.
[4] M. Rowan,et al. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. , 2002, Biochemical Society transactions.
[5] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[6] R. Rydel,et al. Nucleation-Dependent Polymerization Is an Essential Component of Amyloid-Mediated Neuronal Cell Death , 2005, The Journal of Neuroscience.
[7] H. Brody,et al. The aging brain , 1992, Acta neurologica Scandinavica. Supplementum.
[8] J. Trojanowski,et al. Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy , 2011, The Journal of Neuroscience.
[9] Frank M LaFerla,et al. Animal models of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[10] E. Grace,et al. Aberrant Activation of Focal Adhesion Proteins Mediates Fibrillar Amyloid β-Induced Neuronal Dystrophy , 2003, The Journal of Neuroscience.
[11] Hyo-Jin Park,et al. The stress response neuropeptide CRF increases amyloid‐β production by regulating γ‐secretase activity , 2015, The EMBO journal.
[12] K. Zahs,et al. β-Amyloid oligomers in aging and Alzheimer’s disease , 2013, Front. Aging Neurosci..
[13] Pasko Rakic,et al. A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric Aβ, and Frank Neuronal Loss , 2013, The Journal of Neuroscience.
[14] H. Braak,et al. Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. , 1996, Neuroscience letters.
[15] Michael Krams,et al. Charting a path toward combination therapy for Alzheimer’s disease , 2015, Expert review of neurotherapeutics.
[16] S. Strome,et al. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome. , 2009, Current molecular medicine.
[17] Chengjie Xiong,et al. Age and amyloid effects on human central nervous system amyloid‐beta kinetics , 2015, Annals of neurology.
[18] Randall J Bateman,et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials , 2013, Alzheimer's Research & Therapy.
[19] R. Tanzi. TREM2 and Risk of Alzheimer's Disease--Friend or Foe? , 2015, The New England journal of medicine.
[20] D. Borchelt,et al. Thinking laterally about neurodegenerative proteinopathies. , 2013, The Journal of clinical investigation.
[21] Wen-Lang Lin,et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.
[22] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[23] Right sizing funding for Alzheimer's disease , 2011, Alzheimer's Research & Therapy.
[24] E. Heuer,et al. Nonhuman primate models of Alzheimer-like cerebral proteopathy. , 2012, Current pharmaceutical design.
[25] M. Ball,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories: Concurrences and Cautions , 1997, Neurobiology of Aging.
[26] Todd E. Golde,et al. Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.
[27] B. Yankner,et al. Neural mechanisms of ageing and cognitive decline , 2010, Nature.
[28] A. Tamaoka,et al. [Amyloid beta protein]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.
[29] I. Lombardo,et al. The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study , 2015, Alzheimer's & Dementia.
[30] B. Strooper,et al. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015 .
[31] M. Murray,et al. Differential clinicopathologic and genetic features of late-onset amnestic dementias , 2014, Acta Neuropathologica.
[32] D. Holtzman,et al. Acute stress increases interstitial fluid amyloid-β via corticotropin-releasing factor and neuronal activity , 2007, Proceedings of the National Academy of Sciences.
[33] P. Hof,et al. Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms , 2005, The Journal of Neuroscience.
[34] Tao Lu,et al. The aging brain. , 2008, Annual review of pathology.
[35] Linus Jönsson,et al. The worldwide societal costs of dementia: Estimates for 2009 , 2010, Alzheimer's & Dementia.
[36] G. Logroscino,et al. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward , 2014, Expert review of clinical immunology.
[37] Michael W. Weiner,et al. The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update , 2015, Alzheimer's & Dementia.
[38] Robert A. Dean,et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.
[39] B. Strooper,et al. Learning by Failing: Ideas and Concepts to Tackle gamma-Secretases in Alzheimer's Disease and Beyond , 2015 .
[40] P. Mecocci,et al. Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 , 2014, Journal of internal medicine.
[41] A. Hofman,et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.
[42] A. Hofman,et al. Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.
[43] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[44] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[45] Nancy M Bonini,et al. Drosophila as a model for human neurodegenerative disease. , 2005, Annual review of genetics.
[46] R. Green,et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial , 2007, Neurology.
[47] M. Cheitlin. Efficacy of statin therapy in chronic systolic cardiac insufficiency: A meta-analysis , 2012 .
[48] E. Siemers,et al. Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease , 2010, Clinical neuropharmacology.
[49] A. Takashima. Tau aggregation is a therapeutic target for Alzheimer's disease. , 2010, Current Alzheimer research.
[50] John Hardy,et al. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.
[51] J. Winderickx,et al. Protein folding diseases and neurodegeneration: lessons learned from yeast. , 2008, Biochimica et biophysica acta.
[52] Sara Reardon,et al. Antibody drugs for Alzheimer’s show glimmers of promise , 2015, Nature.
[53] F. J. Livesey. Human stem cell models of dementia , 2014, Human molecular genetics.
[54] J. Schneider,et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease , 2015, Alzheimer's & Dementia.
[55] E. Masliah,et al. Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease , 2016, Alzheimer's & Dementia.
[56] Miratul M. K. Muqit,et al. Modelling neurodegenerative diseases in Drosophila: a fruitful approach? , 2002, Nature Reviews Neuroscience.
[57] Nick C Fox,et al. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials , 2015, Neurology.
[58] Douglas Galasko,et al. Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems , 2013, Alzheimer's Research & Therapy.
[59] C. Torborg,et al. Recommendations of the Alzheimer's Disease–Related Dementias Conference , 2014, Neurology.
[60] A. Roses. Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease , 1994, Journal of neuropathology and experimental neurology.
[61] A Klug,et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[62] P. Wong,et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects , 2014, Journal of neurochemistry.
[63] K. Blennow,et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival , 2014, Neurology.
[64] R. Mayeux,et al. Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.
[65] H. Braak,et al. Age, neurofibrillary changes, Aβ-amyloid and the onset of Alzheimer's disease , 1996, Neuroscience Letters.
[66] B. Winblad,et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease , 2015, Alzheimer's Research & Therapy.
[67] Henrik Zetterberg,et al. Fluid biomarkers in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[68] E. Underwood. NEUROSCIENCE. Alzheimer's amyloid theory gets modest boost. , 2015, Science.
[69] R. Nitsch,et al. Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.
[70] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[71] A. Goate,et al. Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis , 2015, Biological Psychiatry.
[72] Ronald C. Petersen,et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.
[73] A. Lbert,et al. Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .
[74] Marguerite Prior,et al. RTN/Nogo in forming Alzheimer's neuritic plaques , 2010, Neuroscience & Biobehavioral Reviews.
[75] K. Jellinger,et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease , 2015, Acta Neuropathologica.
[76] C. Jack,et al. Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.
[77] J. Karlawish,et al. The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.
[78] J. Toyn. What lessons can be learned from failed Alzheimer’s disease trials? , 2015, Expert review of clinical pharmacology.
[79] Sandra E Black,et al. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome , 2013, Alzheimer's Research & Therapy.
[80] Michael W. Weiner,et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 , 2015, Alzheimer's & Dementia.
[81] C. Geula,et al. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. , 1998, Nature medicine.
[82] D. Campion,et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.
[83] W. Thies,et al. 2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.
[84] Alzheimer’s Association. 2015 Alzheimer's disease facts and figures , 2015, Alzheimer's & Dementia.
[85] Kaj Blennow,et al. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.
[86] D. Holtzman,et al. TREM2 lipid sensing sustains microglia response in an Alzheimer’s disease model , 2015, Cell.
[87] C. Barnes,et al. Neural plasticity in the ageing brain , 2006, Nature Reviews Neuroscience.
[88] Thomas Wisniewski,et al. Immunotherapeutic Approaches for Alzheimer’s Disease , 2015, Neuron.
[89] J. Cummings,et al. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.
[90] D. Schaid,et al. Apolipoprotein E: risk factor for Alzheimer disease. , 1994, American journal of human genetics.
[91] J. Schulz,et al. Drosophila melanogaster as a model organism for Alzheimer’s disease , 2013, Molecular Neurodegeneration.
[92] C. Link. Invertebrate models of Alzheimer's disease , 2005, Genes, brain, and behavior.
[93] Christopher A Ross,et al. Human-induced pluripotent stem cells: potential for neurodegenerative diseases. , 2014, Human molecular genetics.
[94] T. Golde,et al. Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology , 2012, Molecular Neurodegeneration.
[95] P. Zandi,et al. Do NSAIDs prevent Alzheimer’s disease? And, if so, why? The epidemiological evidence , 2001, Neurobiology of Aging.
[96] Wendy J Mack,et al. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review , 2011, Alzheimer's Research & Therapy.
[97] Shaomin Li,et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.
[98] R. Tanzi,et al. iPSCs to the rescue in Alzheimer's research. , 2012, Cell stem cell.
[99] R. Petersen,et al. Sanders-brown Center on Aging Faculty Publications Aging Altered Lysosomal Proteins in Neural-derived Plasma Exosomes in Preclinical Alzheimer Disease Repository Citation , 2022 .
[100] John Q Trojanowski,et al. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs , 2004, Nature Medicine.
[101] K. Garber. Genentech's Alzheimer's antibody trial to study disease prevention , 2012, Nature Biotechnology.
[102] V. Hartenstein,et al. Drosophila melanogaster , 2005 .
[103] A. Saunders,et al. Invertebrate models of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[104] Michael W. Weiner,et al. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2015, Alzheimer's & Dementia.
[105] Michael J. Rowan,et al. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition , 2001 .
[106] Molecular genetics of chromosome 17 tauopathies , 2000, Neurobiology of Aging.
[107] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[108] S. Itohara,et al. Single APP knockin mouse models of Alzheimer’s disease , 2014 .
[109] W. Le,et al. Modeling neurodegenerative diseases in Caenorhabditis elegans , 2013, Experimental Neurology.
[110] L. Petrucelli,et al. TAR DNA‐binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features , 2015, Annals of neurology.
[111] W. H. Jordan,et al. A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice , 2012, Neuron.
[112] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[113] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[114] R. Pitman,et al. Stress, PTSD, and dementia , 2014, Alzheimer's & Dementia.
[115] T. Golde,et al. Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-β Immunotherapy , 2011, The Journal of Neuroscience.
[116] Bin Yuan,et al. Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models , 2006 .
[117] K. Blennow,et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.
[118] R. Ransohoff,et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models , 2015, The Journal of experimental medicine.
[119] L. Gasparini,et al. Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage , 2014, Neurobiology of Aging.
[120] P. Davies,et al. Recent advances in the neurochemistry of Alzheimer's disease. , 1987, The Journal of clinical psychiatry.
[121] R. Vassar,et al. Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.
[122] D. Rapport. Stress response. , 1998, Trends in ecology & evolution.
[123] Tracy O'Connor,et al. Protein aggregation diseases: pathogenicity and therapeutic perspectives , 2010, Nature Reviews Drug Discovery.
[124] D. Price,et al. Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.
[125] J. Csernansky,et al. Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.